Sandoz (SIX:SDZ / OTCQX:SDZNY), the global leader in affordable medicines, will host its 2026 capital markets day for investors and analysts on Tuesday, 8 September, at the London Stock Exchange. The event, which will be webcast live from 13:30 to 17:00 UK time, aims to detail the company's strategy to maximize value in what it describes as its 'golden decade for biosimilars.' In-person attendance is by invitation only on a first-come, first-served basis, with invitations to be distributed in due course. Details of how to access the live webcast are available here.
In addition, Sandoz plans to host an investor and analyst site visit in Slovenia from 9-10 November, providing further insight into the company's new biosimilars development and supply-chain hub. Attendance will also be by invitation only on a first-come, first-served basis, and the event will not be webcasted. The site visit underscores Sandoz's commitment to expanding its biosimilars footprint, with the Slovenia hub expected to play a critical role in advancing the company's pipeline and manufacturing capabilities.
The capital markets day comes at a pivotal time for Sandoz, which celebrated 20 years of pioneering biosimilars in 2026. The company, which traces its heritage back to 1886, also marked 80 years of antibiotics manufacturing and 140 years of heritage in 2026. With net sales of USD 11.1 billion in 2025, Sandoz is the global leader in affordable medicines, reaching over one billion patients annually through a portfolio of approximately 1,300 medicines addressing diseases from the common cold to cancer.
Biosimilars are a key growth driver for Sandoz, offering lower-cost alternatives to expensive biologic drugs. The company's strategy focuses on expanding its biosimilars pipeline, leveraging its manufacturing expertise, and capturing market share as patents on major biologics expire. The 'golden decade' refers to the expected wave of biosimilar opportunities through 2035, driven by the expiration of patents on blockbuster biologic drugs and increasing global demand for affordable healthcare.
The event will provide investors with insights into Sandoz's financial targets, R&D pipeline, and operational efficiencies. Analysts will also have the opportunity to engage with senior management on the company's long-term vision. The Slovenia site visit will offer a deeper look into the company's biosimilars development processes and supply-chain innovations, which are integral to maintaining its competitive edge.
Sandoz's focus on biosimilars aligns with broader healthcare trends emphasizing cost containment and access to advanced therapies. As governments and payers worldwide seek to reduce healthcare spending, biosimilars are expected to play an increasingly important role. Sandoz's capital markets day is therefore a critical platform for communicating its strategy to capitalize on these trends and deliver sustainable growth.
For more information on the webcast and event details, visit the Sandoz website. The company's forward-looking statements, as outlined in the press release, are subject to risks and uncertainties, including global economic conditions, exchange rates, legal provisions, market conditions, and competitive activities.
